Published in Br J Dermatol on March 01, 2002
Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis (2005) 2.61
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res (2007) 0.94
The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol (2013) 0.89
Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol (2014) 0.88
Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience. J Eur Acad Dermatol Venereol (2015) 0.80
Subjective stress reactivity in psoriasis - a cross sectional study of associated psychological traits. BMC Dermatol (2015) 0.79
Self-management in daily life with psoriasis: an integrative review of patient needs for structured education. Nurs Res Pract (2012) 0.78
Psoriasis and psycho-dermatology. Dermatol Ther (Heidelb) (2013) 0.77
Psychological interventions in the management of common skin conditions. Psychol Res Behav Manag (2010) 0.77
Psychodermatology: An emotional response. Nature (2012) 0.76
Exploring the Physiological Link between Psoriasis and Mood Disorders. Dermatol Res Pract (2015) 0.75
Q&A: Under their skin. Interview by Rebecca Kessler. Nature (2012) 0.75
Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin disorders. An Bras Dermatol (2014) 0.75
Management of the psychological comorbidities of dermatological conditions: practitioners' guidelines. Clin Cosmet Investig Dermatol (2017) 0.75
Getting under the Skin: Report from the International Psoriasis Council Workshop on the Role of Stress in Psoriasis. Front Psychol (2016) 0.75
A Fear-Avoidance Beliefs Questionnaire (FABQ) and the role of fear-avoidance beliefs in chronic low back pain and disability. Pain (1993) 9.57
British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol (2009) 4.12
Psychosocial predictors of outcome in acute and subchronic low back trouble. Spine (Phila Pa 1976) (1995) 4.00
British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol (2005) 3.10
Patterns of physical activity among 11 to 16 year old British children. BMJ (1990) 2.75
Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis (2005) 2.61
Comparison of physical treatments versus a brief pain-management programme for back pain in primary care: a randomised clinical trial in physiotherapy practice. Lancet (2005) 2.43
The Modified Somatic Perception Questionnaire (MSPQ). J Psychosom Res (1983) 2.42
Reply to Wallis et al., PAIN 73 (1997) 15-22. Pain (1998) 2.39
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut (2005) 2.36
Effects of a cosmetic 'anti-ageing' product improves photoaged skin [corrected]. Br J Dermatol (2009) 2.25
Do attitudes and beliefs influence work loss due to low back trouble? Occup Med (Lond) (1996) 1.94
What patients with psoriasis believe about their condition. J Am Acad Dermatol (1998) 1.85
Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia (2011) 1.76
Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther (2008) 1.74
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol (2005) 1.72
Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis. Br J Dermatol (2005) 1.67
Chronic low-back pain, psychologic distress, and illness behavior. Spine (Phila Pa 1976) (1984) 1.65
Pain drawings in the assessment of nerve root compression: a comparative study with lumbar spine magnetic resonance imaging. Spine (Phila Pa 1976) (1998) 1.63
Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res (2010) 1.60
Tumour necrosis factor-alpha-induced migration of human Langerhans cells: the influence of ageing. Br J Dermatol (2002) 1.59
The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol (2002) 1.52
Changes in blood flow close to subcutaneous insulin injection sites in stable and brittle diabetics. Diabetes (1983) 1.51
The evidence base for the cost effectiveness of cardiac rehabilitation. Heart (1997) 1.50
High and low exercisers among 14- and 15-year-old children. J Public Health Med (1994) 1.49
Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol (2005) 1.49
Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. BMJ (1991) 1.48
Assessment of severity in low-back disorders. Spine (Phila Pa 1976) (1984) 1.48
Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis (2007) 1.47
Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet (2007) 1.44
Pityriasis rubra pilaris treated with acitretin and narrow-band ultraviolet B (Re-TL-01) Br J Dermatol (2000) 1.43
Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis. Br J Dermatol (2010) 1.42
Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis. J Am Acad Dermatol (1998) 1.41
Absence resulting from low back trouble can be reduced by psychosocial intervention at the work place. Spine (Phila Pa 1976) (1995) 1.41
The neurotoxicity of inhaled toluene. Can J Psychiatry (1990) 1.41
Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol (2005) 1.40
Geographical ancestry is a key determinant of epidermal morphology and dermal composition. Br J Dermatol (2014) 1.40
Providing lifestyle behaviour change support for patients with psoriasis: an assessment of the existing training competencies across medical and nursing health professionals. Br J Dermatol (2014) 1.39
Making a 'point' about the safe disposal of sharps in patients on biological therapies. Br J Dermatol (2008) 1.37
Sickness certification and the GP: what really happens in practice? Fam Pract (2009) 1.35
Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol (1997) 1.30
Patients with psoriasis and their compliance with medication. J Am Acad Dermatol (1999) 1.28
Natural history of individuals with asymptomatic disc abnormalities in magnetic resonance imaging: predictors of low back pain-related medical consultation and work incapacity. Spine (Phila Pa 1976) (2000) 1.27
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol (2013) 1.26
Normality and reliability in the clinical assessment of backache. Br Med J (Clin Res Ed) (1982) 1.24
Recognition of need in health care consultations: a qualitative study of people with psoriasis. Br J Dermatol (2012) 1.23
The impact of clinical, morphological, psychosocial and work-related factors on the outcome of lumbar discectomy. Pain (1999) 1.20
Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol (2003) 1.17
Symptoms and signs: physical disease or illness behaviour? Br Med J (Clin Res Ed) (1984) 1.16
Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol (2013) 1.14
Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis (2007) 1.13
Differential contribution of CDKAL1 variants to psoriasis, Crohn's disease and type II diabetes. Genes Immun (2009) 1.12
Surface electromyography in the identification of chronic low back pain patients: the development of the flexion relaxation ratio. Clin Biomech (Bristol, Avon) (1997) 1.12
The role of neuropeptides in psoriasis. Br J Dermatol (2006) 1.12
Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol (2005) 1.11
Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol (2006) 1.11
Inpatient management of psoriasis: a multicentre service review to establish national admission standards. Br J Dermatol (2007) 1.10
Natural killer and natural killer-T cells in psoriasis. Arch Dermatol Res (2002) 1.09
Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev (2006) 1.09
Psychiatric and neurological effects of chronic solvent abuse. Can J Psychiatry (1991) 1.08
Striae gravidarum in primiparae. Br J Dermatol (2006) 1.08
Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol (2001) 1.07
The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res (2001) 1.06
Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) (2005) 1.05
The use of the pain drawing as a screening measure to predict psychological distress in chronic low back pain. Spine (Phila Pa 1976) (1995) 1.04
Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol (2004) 1.04
Medically certified work loss, recurrence and costs of wage compensation for back pain: a follow-up study of the working population of Jersey. Br J Rheumatol (1998) 1.04
Circulating natural killer cells in psoriasis. Br J Dermatol (2003) 1.04
Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol (2006) 1.04
The assessment of recovery in patients after myocardial infarction using three generic quality-of-life measures. J Cardiopulm Rehabil (1998) 1.04
IL-1beta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin. Clin Exp Immunol (2003) 1.03
Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol (2005) 1.03
The peak oxygen uptake of British children with reference to age, sex and sexual maturity. Eur J Appl Physiol Occup Physiol (1991) 1.03
Management of primary cicatricial alopecias: options for treatment. Br J Dermatol (2008) 1.03
The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J Invest Dermatol (2005) 1.00
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol (2011) 1.00
Psychological influences in psoriasis. Clin Exp Dermatol (2001) 0.99
How not to get scar(r)ed: pointers to the correct diagnosis in patients with suspected primary cicatricial alopecia. Br J Dermatol (2009) 0.99
Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br J Dermatol (2002) 0.98
A new wrinkle on old skin: the role of elastic fibres in skin ageing. Int J Cosmet Sci (2010) 0.98
Antibodies to HIV-1 nef(p27): prevalence, significance, and relationship to seroconversion. AIDS Res Hum Retroviruses (1990) 0.97
Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol (2012) 0.96
Cytokine gene polymorphisms in psoriasis. Br J Dermatol (2001) 0.96
Monocyte chemoattractant protein (MCP)-1 is rapidly expressed by sympathetic ganglion neurons following axonal injury. Neuroreport (2001) 0.95
Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol (2007) 0.95
The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. Br J Dermatol (2012) 0.95
Low blood pressure in psychiatric inpatients. Br Heart J (1981) 0.95
Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol (2006) 0.94
In search of oral psoriasis. Arch Dermatol Res (2011) 0.94
Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol (2010) 0.94
Does psychosocial stress play a role in the exacerbation of psoriasis? Br J Dermatol (2013) 0.93